<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4918">
  <stage>Registered</stage>
  <submitdate>17/10/2014</submitdate>
  <approvaldate>17/10/2014</approvaldate>
  <nctid>NCT02271529</nctid>
  <trial_identification>
    <studytitle>Zilver PTX Delivery System</studytitle>
    <scientifictitle>Zilver Paclitaxel(PTX) Thumbwheel Delivery System</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>13-14</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Vascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Zilver® PTX® Drug-Eluting Peripheral Stent

Experimental: Drug Eluting Stent - Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent


Treatment: devices: Zilver® PTX® Drug-Eluting Peripheral Stent
Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean Percent Change in Stent Length Upon Deployment</outcome>
      <timepoint>Immediately following completion of the stent placement procedure</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal
             arteries

          -  Patient has atherosclerotic lesion of the above-the-knee femoropopliteal artery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient is &lt; 18 years of age

          -  Patient unable to complete required follow-up assessments

          -  Patient unwilling to sign and date the informed consent

          -  Simultaneous participation in another investigational drug or device study

          -  Pregnant, breastfeeding or planning to become pregnant in the next 5 years

          -  Additional medical/anatomical restrictions as specified in the Clinical Investigation
             Plan</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode>Vic 3199 - Frankston</postcode>
    <postcode>Qld 4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cook Group Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this study is to evaluate the performance of the Zilver PTX stent thumbwheel
      delivery system.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02271529</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Holden, MD</name>
      <address>Auckland District Health Board</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>